Onkologie. 2017:11(3):115-120 | DOI: 10.36290/xon.2017.023

Anticancer therapy – related acute myeloid leukemias

Tomáš Szotkowski, Martin Čerňan, Jaromír Hubáček, Milena Holzerová, Tomáš Papajík

Hemato-onkologická klinika LF UP Olomouc

Advances achieved in anticancer treatment are partly redeemed by adverse events. So called therapy-related acute myeloid leukemia

belongs to the most serious ones. Their incidence growth is one of the most rapid among neoplastic disorders nowadays. Causes of

developement of these complications are not clearly clarified. Several pathogenetic mechanisms involvement is anticipated. Generally

speaking, prognosis of these disorders is very poor, partly due to toxicity of previous antitumour treatment, partly due to adverse biological

character of this leukemia group. The therapeutic approach depends on patient`s performance status as well as genetic prognosis of the

disease itself. Allogeneic hematopoietic cells transplantation is the only potentially curative option for majority of patients. Reduction

of incidence of the disease and expansion of therapeutic possibilities are very important tasks of both oncology and heamatology.

Keywords: acute myeloid leukemia, secondary leukemia, anticancer treatment complications, prognostic factors

Published: June 1, 2017  Show citation